Endra Life Sciences Inc. (NDRA) intrinsic value & 10-year financials
Endra Life Sciences Inc. (NDRA) has a Graham intrinsic value of $1,306.81 per share. At $4.74 on Oct 17, 2026, the stock trades 100% below that value.
- Graham intrinsic value
- $1,306.81
- Share price (Oct 17, 2026)
- $4.74
- Price vs Graham value
- 100% below
- Market cap
- $3.7M
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- -89.1%
- ROIC (10-yr avg)
- 509.0%
- Free cash flow (FY2025)
- -$5.2M
NDRA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$7.0M | -$8.93 | -$5.2M | — | -837.0% |
| FY2024 | — | -$11.5M | -$14.23 | -$7.4M | — | -755.4% |
| FY2023 | — | -$10.1M | -$12.35 | -$9.6M | — | -343.7% |
| FY2022 | — | -$13.2M | — | -$13.0M | — | -481.7% |
| FY2021 | — | -$11.2M | — | -$11.2M | — | -884.0% |
| FY2020 | $0 | -$11.7M | — | -$10.8M | — | 2684.8% |
| FY2019 | $0 | -$13.3M | — | -$8.6M | — | 1676.1% |
| FY2018 | $6.2K | -$9.8M | — | -$7.8M | -146080.5% | 4041.4% |
| FY2017 | $351.6K | -$5.4M | — | -$3.3M | -1315.6% | -211.2% |
| FY2016 | $515.6K | -$2.8M | — | — | -347.5% | 200.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ENDRA Life Sciences Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ENDRA Life Sciences Inc. has historically struggled to out-earn its cost of capital, averaging just 5.1% ROIC.
ENDRA Life Sciences Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ENDRA Life Sciences Inc. is modeled at -89.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $1306.81 per share.